Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Identification of structurally diverse FSP1 inhibitors that sensitize cancer cells to ferroptosis.
Hendricks JM, Doubravsky CE, Wehri E, Li Z, Roberts MA, Deol KK, Lange M, Lasheras-Otero I, Momper JD, Dixon SJ, Bersuker K, Schaletzky J, Olzmann JA. Hendricks JM, et al. Among authors: schaletzky j. Cell Chem Biol. 2023 Sep 21;30(9):1090-1103.e7. doi: 10.1016/j.chembiol.2023.04.007. Epub 2023 May 12. Cell Chem Biol. 2023. PMID: 37178691 Free PMC article.
Discovery of Tirasemtiv, the First Direct Fast Skeletal Muscle Troponin Activator.
Collibee SE, Bergnes G, Muci A, Browne WF 4th, Garard M, Hinken AC, Russell AJ, Suehiro I, Hartman J, Kawas R, Lu PP, Lee KH, Marquez D, Tomlinson M, Xu D, Kennedy A, Hwee D, Schaletzky J, Leung K, Malik FI, Morgans DJ Jr, Morgan BP. Collibee SE, et al. Among authors: schaletzky j. ACS Med Chem Lett. 2018 Feb 13;9(4):354-358. doi: 10.1021/acsmedchemlett.7b00546. eCollection 2018 Apr 12. ACS Med Chem Lett. 2018. PMID: 29670700 Free PMC article.
Discovery of Reldesemtiv, a Fast Skeletal Muscle Troponin Activator for the Treatment of Impaired Muscle Function.
Collibee SE, Bergnes G, Chuang C, Ashcraft L, Gardina J, Garard M, Jamison CR, Lu K, Lu PP, Muci A, Romero A, Valkevich E, Wang W, Warrington J, Yao B, Durham N, Hartman J, Marquez A, Hinken A, Schaletzky J, Xu D, Hwee DT, Morgans D, Malik FI, Morgan BP. Collibee SE, et al. Among authors: schaletzky j. J Med Chem. 2021 Oct 28;64(20):14930-14941. doi: 10.1021/acs.jmedchem.1c01067. Epub 2021 Oct 12. J Med Chem. 2021. PMID: 34636234 Free article.
Screening a Library of FDA-Approved and Bioactive Compounds for Antiviral Activity against SARS-CoV-2.
Biering SB, Van Dis E, Wehri E, Yamashiro LH, Nguyenla X, Dugast-Darzacq C, Graham TGW, Stroumza JR, Golovkine GR, Roberts AW, Fines DM, Spradlin JN, Ward CC, Bajaj T, Dovala D, Schulze-Gamen U, Bajaj R, Fox DM, Ott M, Murthy N, Nomura DK, Schaletzky J, Stanley SA. Biering SB, et al. Among authors: schaletzky j. ACS Infect Dis. 2021 Aug 13;7(8):2337-2351. doi: 10.1021/acsinfecdis.1c00017. Epub 2021 Jun 15. ACS Infect Dis. 2021. PMID: 34129317
SARS-CoV-2 nucleocapsid protein forms condensates with viral genomic RNA.
Jack A, Ferro LS, Trnka MJ, Wehri E, Nadgir A, Nguyenla X, Fox D, Costa K, Stanley S, Schaletzky J, Yildiz A. Jack A, et al. Among authors: schaletzky j. PLoS Biol. 2021 Oct 11;19(10):e3001425. doi: 10.1371/journal.pbio.3001425. eCollection 2021 Oct. PLoS Biol. 2021. PMID: 34634033 Free PMC article.
Genome-wide bidirectional CRISPR screens identify mucins as host factors modulating SARS-CoV-2 infection.
Biering SB, Sarnik SA, Wang E, Zengel JR, Leist SR, Schäfer A, Sathyan V, Hawkins P, Okuda K, Tau C, Jangid AR, Duffy CV, Wei J, Gilmore RC, Alfajaro MM, Strine MS, Nguyenla X, Van Dis E, Catamura C, Yamashiro LH, Belk JA, Begeman A, Stark JC, Shon DJ, Fox DM, Ezzatpour S, Huang E, Olegario N, Rustagi A, Volmer AS, Livraghi-Butrico A, Wehri E, Behringer RR, Cheon DJ, Schaletzky J, Aguilar HC, Puschnik AS, Button B, Pinsky BA, Blish CA, Baric RS, O'Neal WK, Bertozzi CR, Wilen CB, Boucher RC, Carette JE, Stanley SA, Harris E, Konermann S, Hsu PD. Biering SB, et al. Among authors: schaletzky j. Nat Genet. 2022 Aug;54(8):1078-1089. doi: 10.1038/s41588-022-01131-x. Epub 2022 Jul 25. Nat Genet. 2022. PMID: 35879412 Free PMC article.
An intranasal ASO therapeutic targeting SARS-CoV-2.
Zhu C, Lee JY, Woo JZ, Xu L, Nguyenla X, Yamashiro LH, Ji F, Biering SB, Van Dis E, Gonzalez F, Fox D, Wehri E, Rustagi A, Pinsky BA, Schaletzky J, Blish CA, Chiu C, Harris E, Sadreyev RI, Stanley S, Kauppinen S, Rouskin S, Näär AM. Zhu C, et al. Among authors: schaletzky j. Nat Commun. 2022 Aug 3;13(1):4503. doi: 10.1038/s41467-022-32216-0. Nat Commun. 2022. PMID: 35922434 Free PMC article.
Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells.
Nguyenla X, Wehri E, Van Dis E, Biering SB, Yamashiro LH, Zhu C, Stroumza J, Dugast-Darzacq C, Graham TGW, Wang X, Jockusch S, Tao C, Chien M, Xie W, Patel DJ, Meyer C, Garzia A, Tuschl T, Russo JJ, Ju J, Näär AM, Stanley S, Schaletzky J. Nguyenla X, et al. Among authors: schaletzky j. Sci Rep. 2022 Nov 2;12(1):18506. doi: 10.1038/s41598-022-21034-5. Sci Rep. 2022. PMID: 36323770 Free PMC article.
MyosinA is a druggable target in the widespread protozoan parasite Toxoplasma gondii.
Kelsen A, Kent RS, Snyder AK, Wehri E, Bishop SJ, Stadler RV, Powell C, Martorelli di Genova B, Rompikuntal PK, Boulanger MJ, Warshaw DM, Westwood NJ, Schaletzky J, Ward GE. Kelsen A, et al. Among authors: schaletzky j. PLoS Biol. 2023 May 8;21(5):e3002110. doi: 10.1371/journal.pbio.3002110. eCollection 2023 May. PLoS Biol. 2023. PMID: 37155705 Free PMC article.
24 results